Fig. 5

Hyperglycemic condition does not augment peripheral inflammation in response to systemic LPS administration

(A-C) Flow cytometric analyses of bone marrow cells from vehicle- and STZ-injected mice followed by LPS injection (0.5 mg/kg, 6 h). (4 mice per group) (D-F) Flow cytometric analyses of circulating blood cells from vehicle- and STZ-injected mice followed by LPS injection (0.5 mg/kg, 6 h). (5 mice, vehicle groups; 4 mice, STZ groups) (G-H) Quantification of IL-1𝝱 (G) and TNF-𝝰 (H) protein level in the serum from vehicle- and STZ-injected mice followed by LPS injection (0.5 mg/kg, 6 h) using ELISA. (5 mice, veh-PBS; 6 mice, veh-LPS, STZ-LPS; 8 mice, STZ-PBS) (I-J) Quantification of mRNA levels of IL-1𝝱 (I) and TNF-𝝰 (J) from spleen extracts of vehicle- and STZ-injected mice followed by LPS injection (0.5 mg/kg, 6 h). (5 mice, veh-PBS; 6 mice, veh-LPS, STZ-LPS; 8 mice, STZ-PBS) Data are presented as means ± SEM. Significant differences between the groups were determined by two-way ANOVA with Bonferroni post hoc test. n.s. not significant